PARIJS– (BUSINESS WIRE) – JPND nodigt multinationale onderzoeksteams uit om voorstellen in te dienen die gericht zijn op het identificeren en meten van fysiologische effecten en gerelateerde biomarkers die kunnen worden gekoppeld aan de ontwikkeling van neurodegeneratieve ziekten.

Neurodegeneratieve ziekten zijn slopende en grotendeels onbehandelbare aandoeningen die sterk verband houden met de leeftijd. Wereldwijd lijden naar schatting 47 miljoen mensen aan de ziekte van Alzheimer en aanverwante aandoeningen. Dit cijfer zal naar verwachting elke 20 jaar verdubbelen naarmate de bevolking ouder wordt. De ontwikkeling van efficiënte behandelingen voor de meeste neurodegeneratieve ziekten wordt belemmerd door het feit dat de detectie ervan in de late stadia ingrijpt, tegen die tijd dat de integriteit van het zenuwweefsel is aangetast. Slecht gekarakteriseerde vroege fysiologische stoornissen waarvan bekend is dat ze optreden voordat ondubbelzinnige symptomen van elke neurodegeneratieve ziekte worden gedetecteerd. Deze veranderingen kunnen onder meer het verstoren van slaap, reukzin, gehoor, gezichtsvermogen, metabolische factoren en sociale betrokkenheid omvatten. Al deze tekens kunnen worden gebruikt als vroege indicatoren van latere ziekten en zijn in de meeste gevallen meetbaar in natuurlijke omgevingen van het dagelijkse leven. Daarom zou de identificatie van de circuits en moleculaire paden die worden beïnvloed, veelbelovende doelen kunnen onthullen voor vroege interventies en therapieën voor neurodegeneratieve ziekten.

The 2021 Call of the EU Joint Programme on Neurodegenerative Disease Research (JPND) Is Open

PARIS–(BUSINESS WIRE)– JPND is inviting multi-national research teams to submit proposals aimed at identifying and measuring physiological effects and related biomarkers that can be linked to the development of neurodegenerative diseases.

Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 47 million people suffering from Alzheimer’s disease and related disorders. This figure is expected to double every 20 years as the population ages. The development of efficient treatments for most neurodegenerative diseases is hindered by the fact that their detection intervenes at late stages by which time the integrity of the nervous tissue has been compromised. Poorly characterised early physiological disturbances known to appear before unambiguous symptoms of each neurodegenerative disease are detected. These changes may include, among others, the disruption of sleep, olfaction, hearing, vision, metabolic factors as well as social engagement. All these signs have the potential to be used as early indicators of later diseases, and in most cases, are measurable in natural daily life environments. Hence, the identification of the circuits and molecular pathways being affected might reveal promising targets for early interventions and therapies for neurodegenerative diseases.

In this context, JPND announced a new joint transnational call inviting multi-national research teams to submit proposals for ambitious, innovative and multi-disciplinary collaborative projects that aim at the detection, measurement and understanding of early disease indicators related to neurodegenerative diseases, with potential for the development of new diagnostics or interventions.

Professor Philippe Amouyel, Chair of the JPND Management Board says, “One of the major limitations of neurodegenerative diseases is their sneaky sub-clinical course that can last for years before the first symptoms appear. Very often, clinicians have noticed a posteriori that these symptoms had been preceded many years before by disturbances of major physiological functions. Thus bringing together research forces in Europe and beyond through JPND will allow us to better understand the pathophysiological mechanisms of the appearance of neurodegenerative diseases. In addition, this will help to identify early indicators of their occurrence before the neuronal potential is too altered, facilitating the implementation of treatments.”

Proposals submitted under this call, which is open to applicants in 22 countries, must focus on one or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, prion diseases, motor-neuron diseases, Huntington’s disease, spinocerebellar ataxia and spinal muscular atrophy. JPND is committed to Patient and Public Involvement, and proposals are expected to engage patients, carers and the public.

Proposals must also focus on one or several of the following research areas:

• Demonstrating the relationship between early neurodegenerative processes and physiological disturbances,
• Applying cutting-edge methods or technologies to improve the detection of early symptoms,
• Human or animal studies to decipher the neurodegeneration-derived processes causing early disease-specific signatures,
• Using digital technologies to link recognisable symptoms to physiological changes associated to neurodegeneration,
• Relating prognostic signs of disease with real-life measurement of physiological disturbances using home-monitoring and/or wearable devices, including wireless sensors for patient monitoring.

Pre-proposals must be submitted no later than 15:00h C.E.T. on March 2, 2021.

For more information about the call, please click here.

The EU Joint Programme on Neurodegenerative Disease Research (JPND) was established to better coordinate research efforts across countries and disciplines to more rapidly find causes, develop cures and identify better ways to care for people with neurodegenerative disease. Today more than 40 million people worldwide are estimated to be living with Alzheimer’s disease and related disorders – the most common class of neurodegenerative disease – and this figure is expected to rise in the coming decades. The JPND Research and Innovation Strategy identified research priorities and provided a framework for future investment and is available for download here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005985/en/

Contacts

Karin YEO

+33 7 8227 2887

karin.yeo@jpnd.eu
www.jpnd.eu
Twitter: @JPNDEurope

Linkedin: https://www.linkedin.com/company/jpnd-joint-programme-neurodegenerative-disease-research